Evaluation Of A Rapid Behavioural Treatment For Sleep Onset Insomnia
Funder
National Health and Medical Research Council
Funding Amount
$268,500.00
Summary
Chronic insomnia is a prevalent health problem that affects 5-10% of the population. It is associated with significant physical and mental health problems as well as lowered quality of life. By far the most common treatment for insomnia continues to be sleeping tablets despite the problems of drug dependence, daytime impairment and long term loss of effect. It is also despite the evidence that behavioural therapies are more effective in the long term. In clinical experiments stimulus control the ....Chronic insomnia is a prevalent health problem that affects 5-10% of the population. It is associated with significant physical and mental health problems as well as lowered quality of life. By far the most common treatment for insomnia continues to be sleeping tablets despite the problems of drug dependence, daytime impairment and long term loss of effect. It is also despite the evidence that behavioural therapies are more effective in the long term. In clinical experiments stimulus control therapy (SCT) is consistently the most effective of the behavioural therapies. However, SCT is difficult to carry out over the 4-6 week period necessary for effective treatment. If the treatment process could be shortened, it may increase the number of successful treatments. We have developed a laboratory procedure which includes the effective elements of SCT. These elements include sleep restriction and the experience of one rapid sleep onset each night. Our procedure involves some sleep deprivation and the experience of many (over 40) rapid sleep onsets over just one day. Therefore, it condenses 40 nights of the re-training benefits of SCT into just one day. A preliminary study has shown this procedure to be as effective as normal SCT. However, with no follow-up therapy to the procedure the initial gains tended to diminish with time. Our proposal is to test and extend the possible benefits of this new treatment procedure. We will compare it with the standard SCT as well as combine it with SCT. We feel that the greatest benefit may be to use the laboratory procedure as a kick start to SCT, which will by-pass the most difficult first 2--3 weeks of SCT. This will greatly reduce the time as well as absolutely improve the outcome. In further studies the laboratory procedure may be transferred to the patient s home, thereby further increasing its effectiveness. We feel the proposal will lead to a significant improvement in the non-drug treatment of insomnia.Read moreRead less
Improving Clinical Outcomes Of Antimicrobial Resistant Infections With A Drug-free Intervention
Funder
National Health and Medical Research Council
Funding Amount
$999,581.00
Summary
Superbugs, or antimicrobial-resistant pathogens, cause recurring infections and non-healing wounds after surgery as existing therapies fail to effectively kill them. We will develop a medical device to fight superbugs with UV light that is effective against bacteria and fungi without causing harm to human cells. This could eradicate superbugs at infection sites, aid wound healing and actively improve health outcomes after surgery.
Investigation Of The Low Dose UV G2 Phase Checkpoint And Its Potential Exploitation In The Treatment Of Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$35,085.00
Summary
The research aims to indentify the role UV exposure contributes to the development of melanoma and if this knowledge can be used to develop new methods in the prevention and treatment of this disease
Functional Resolution Of PTEX, The Exporter Of Virulence Factors In Malaria Parasites.
Funder
National Health and Medical Research Council
Funding Amount
$625,212.00
Summary
Almost half a million people die each year of malaria and nearly half the world’s population are at risk. To eliminate malaria this century we will need new drugs and vaccine to fight the disease. One potential drug target are the molecular gateways called PTEX, that are used by parasites to export virulence proteins into their human host cells. This grant aims to understand how the PTEX molecular machines work so we can develop new drugs to block them and kill the parasites.
Enhancing Clinical Management Of Paediatric Malaria In Endemic Areas With Transmission Of Multiple Plasmodium Species
Funder
National Health and Medical Research Council
Funding Amount
$867,511.00
Summary
Malaria remains a major problem for children in developing countries especially where different types of the disease are common. This set of complementary studies, based at an established research site in PNG aims to develop new treatment strategies for childhood malaria. A novel method of giving medicine via a spray under the tongue for sick children before arrival at hospital and modified dosing schedules of an old drug used for treating parasites hidden in the liver will be studied.
Risk Factors, Mechanisms, And Treatment Of Knowlesi Malaria
Funder
National Health and Medical Research Council
Funding Amount
$265,138.00
Summary
The monkey parasite P. knowlesi is an increasing cause of human malaria in SE Asia. My studies on the clinical epidemiology, diagnosis and treatment of non-severe and severe malaria in Malaysia have changed policy. I will further define the clinical epidemiology of malaria patients in this area over time, assess risk factors for knowlesi malaria, and evaluate the role of human and parasite factors in disease severity, and treatment for reducing acute kidney injury in knowlesi malaria.
Griseofulvin, A Novel Host-directed Antimalarial Drug
Funder
National Health and Medical Research Council
Funding Amount
$461,551.00
Summary
This grant is for a Phase II clinical trial to test an FDA & TGA approved drug for a new use as an antimalarial drug. The parasite uses an enzyme from the human RBC to help it replicate & early trials show this drug appears to disrupt the life cycle of the parasite. This Phase II clinical trial will test the drug on human subjects, & if successful, the drug will be a new and novel way in which to treat and prevent malarial infections in humans.
Disease Burden, Risk Factors And Treatment Of Knowlesi Malaria
Funder
National Health and Medical Research Council
Funding Amount
$95,564.00
Summary
Plasmodium knowlesi is a form of monkey malaria recently found to also cause increasing numbers of natural infections in humans in South-East Asia. This research will describe the burden of P. knowlesi malaria in an area of Malaysian Borneo. The risk factors for acquiring P. knowlesi malaria will be assessed. Finally the optimal treatment for non-severe cases of P. knowlesi and P. vivax malaria will also be evaluated by comparing the 2 currently recommended anti-malarial medications in Malaysia.